Northern Trust Corp lifted its holdings in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) by 9.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,268,840 shares of the biotechnology company’s stock after acquiring an additional 109,013 shares during the period. Northern Trust Corp owned approximately 0.85% of Idera Pharmaceuticals worth $2,183,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of IDRA. GSA Capital Partners LLP raised its position in shares of Idera Pharmaceuticals by 846.1% in the 2nd quarter. GSA Capital Partners LLP now owns 180,588 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 161,500 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Idera Pharmaceuticals by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 5,007,333 shares of the biotechnology company’s stock worth $12,368,000 after acquiring an additional 159,828 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Idera Pharmaceuticals by 93.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 322,929 shares of the biotechnology company’s stock worth $798,000 after acquiring an additional 156,400 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of Idera Pharmaceuticals in the 2nd quarter worth about $232,000. Finally, State of Wisconsin Investment Board bought a new position in shares of Idera Pharmaceuticals in the 2nd quarter worth about $136,000. 24.14% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on IDRA shares. BidaskClub lowered Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. HC Wainwright started coverage on Idera Pharmaceuticals in a research report on Thursday, November 9th. They issued a “buy” rating and a $4.00 price objective for the company. Zacks Investment Research raised Idera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Thursday, November 9th. Piper Jaffray Companies reissued a “buy” rating and issued a $4.00 price objective on shares of Idera Pharmaceuticals in a research report on Tuesday, September 12th. Finally, ValuEngine lowered Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $4.83.

Shares of Idera Pharmaceuticals, Inc. (IDRA) opened at $2.18 on Thursday. Idera Pharmaceuticals, Inc. has a 12 month low of $1.30 and a 12 month high of $2.87.

Idera Pharmaceuticals (NASDAQ:IDRA) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.02. The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 60.80% and a negative net margin of 313.78%. research analysts expect that Idera Pharmaceuticals, Inc. will post -0.42 EPS for the current fiscal year.

In other news, Director Bros. Advisors Lp Baker bought 8,000,000 shares of Idera Pharmaceuticals stock in a transaction dated Thursday, October 26th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $12,000,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 12.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Idera Pharmaceuticals, Inc. (IDRA) Shares Bought by Northern Trust Corp” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/30/idera-pharmaceuticals-inc-idra-shares-bought-by-northern-trust-corp.html.

Idera Pharmaceuticals Profile

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.